James Kanter

James joined Flightpath Biosciences as a CMC consultant and brings over 25 years of small molecule drug development experience spanning early development to product launch and commercialization.

James joined Flightpath Biosciences most recently from Bridgebio where he was the VP of Technical Operations/CMC for several early and late stage clinical development programs.

Prior to Bridgebio, James spent time, with growing levels of responsibilities, at several San Francisco Bay Area biotech companies, including Ardelyx, Portola, Gilead Sciences, Exelixis & COR Therapeutics/Millennium.

James has been involved in over 50 development projects, more than 30 IND filings and 6 successful NDA approvals including Integrilin, Velcade, Sovaldi & Ibsrela among others.